

Pegavision Corp (6491 TT)

 Target price: **TWD375.00** (from TWD335.00)

 Share price (31 Jul): **TWD324.00** | Up/downside: **+15.7%**
5 4 3 **2** 1
Outperform
 (unchanged)

2Q26 results review: better than expected

- 2Q26 results beat both Daiwa and Bloomberg estimates
- Intact outlook for silicone hydrogel contact lenses and Japan market
- Reaffirming our Outperform (2) rating; raising 12-month TP to TWD375

Helen Chien

(886) 2 8758 6254

helen.chien@daiwacm-cathay.com.tw

Neil Teng, CFA

(886) 2 8758 6256

neil.teng@daiwacm-cathay.com.tw



What's new: Pegavision released its 2Q26 results on 31 July after market hours. The company maintained a positive view on the Japan market and its product roadmap for silicone hydrogel contact lenses in multiple regions, including Japan and Europe. We reaffirm our Outperform (2) call.

What's the impact: 2Q26 results beat. Pegavision's 2Q26 revenue of TWD2,115m (+12.1% QoQ; +30.0% YoY) beat our estimate and the Bloomberg consensus by 14.3% and 1.1%, respectively, mainly due to the Japan market in light of its order share gains following vendor consolidation. Its gross margin of 53.0% (vs. 53.3% in 1Q26 and 50.9% in 2Q25) was roughly in line with our estimate (53.0%) and the Bloomberg consensus estimate (53.2%). Operating margin of 27.6% (vs. 28.8% in 1Q26 and 23.3% in 2Q25) beat our estimate (25.5%) but was slightly below the Bloomberg consensus estimate (28.2%). Its 2Q26 operating profit of TWD585m (+7.7% QoQ; +54.3% YoY) beat our estimate by 23.9% but was in line with consensus. Due to some non-op gains and a lower-than-expected tax rate, its 2Q26 net profit came in at TWD544m (+15.2% QoQ; +73.6% YoY), beating our and Bloomberg consensus estimates by 33.8% and 10.6%, respectively. Its 2Q26 EPS was TWD7.07. Japan accounted for 60%+ of its revenue in 1H26 while China accounted for 10%+.

Bright 2H26 revenue; capacity expansion plans in Vietnam and Taiwan. Pegavision targets revenue to grow QoQ in 2H26, driven by the ramp-up of silicone hydrogel daily contact lenses, which accounted for 10% of 2Q26 revenue and is targeted to contribute 15% of 4Q26 revenue, and a solid order outlook from the Japan market. In China, Pegavision remains cautious on the price war despite its China revenue rising 10% YoY in 1H26. For 2026-28, Pegavision aims for revenue to grow a double digit % YoY vs. its 1H26 revenue growth of 24.2% YoY. It plans to launch its new Vietnam plant in 2027. We raise our 2026-27E EPS by 11-18%, mainly on our more aggressive revenue forecasts, and introduce our 2028 forecasts.

What we recommend: We reaffirm our Outperform (2) rating and raise our 12M TP to TWD375 (from TWD335), now based on a PER of 14x (from 15x) on its slightly decelerating earnings momentum, lower than the midpoint (16x) of its past-3-year trading range of 10-22x, applied to our 12-month forward EPS forecast. However, we believe the launch of silicone hydrogel contact-lens products will likely be a share-price catalyst, with a dividend yield of 3.1-3.8% over 2026-28E to support the share price. Downside risks: a macroeconomic slowdown and increased competition.


How we differ: Our 2027E EPS is 8% below Bloomberg consensus, likely as we are more conservative on Pegavision's revenue expansion.

Forecast revisions (%)

Year to 31 Dec	26E	27E	28E
Revenue change	7.9	9.9	n.a.
Net profit change	17.6	11.3	n.a.
Core EPS (FD) change	17.7	11.4	n.a.

Source: Daiwa forecasts

Share price performance



12-month range	274.50-378.00
Market cap (USDbn)	0.78
3m avg daily turnover (USDm)	6.35
Shares outstanding (m)	78
Major shareholder	Kinsus investment (30.3%)

Financial summary (TWD)

Year to 31 Dec	26E	27E	28E
Revenue (m)	8,271	9,098	10,008
Operating profit (m)	2,270	2,458	2,696
Net profit (m)	2,046	2,156	2,388
Core EPS (fully-diluted)	26.054	27.452	30.409
EPS change (%)	26.4	5.4	10.8
Daiwa vs Cons. EPS (%)	2.2	(8.2)	n.a.
PER (x)	12.4	11.8	10.7
Dividend yield (%)	3.1	3.6	3.8
DPS	10.0	11.8	12.4
PBR (x)	2.1	1.9	1.7
EV/EBITDA (x)	6.8	6.0	5.2
ROE (%)	17.3	17.1	17.1

Source: FactSet, Daiwa forecasts

Pegavision: revisions to revenue and earnings forecasts

(TWDm)	2026E			2027E			2028E		
	Previous	New	Consensus	Previous	New	Consensus	Previous	New	Consensus
Revenue	7,666	8,271	8,376	8,279	9,098	9,634	n.a.	10,008	n.a.
Diff (%)		7.9%	-1.3%		9.9%	-5.6%		n.a.	n.a.
Gross margin (%)	53.0%	52.8%	53.4%	53.5%	52.9%	54.1%	n.a.	53.1%	n.a.
Operating profit	2,027	2,270	2,358	2,238	2,458	2,816	n.a.	2,696	n.a.
Operating margin (%)	26.4%	27.4%	28.2%	27.0%	27.0%	29.2%	n.a.	26.9%	n.a.
Net profit	1,740	2,046	1,991	1,936	2,156	2,334	n.a.	2,388	n.a.
Diluted EPS (TWD)	22.14	26.05	25.49	24.64	27.45	29.92	n.a.	30.41	n.a.
Diff (%)		17.7%	2.2%		11.4%	-8.2%		n.a.	n.a.

Source: Bloomberg, Daiwa forecasts

Pegavision: quarterly and annual P&L statement

(TWDm)	2026E				2027E				2026E	2027E	2028E
	1Q	2QE	3QE	4QE	1QE	2QE	3QE	4QE			
Revenue	1,886	2,115	2,130	2,141	2,065	2,200	2,400	2,433	8,271	9,098	10,008
Gross profit	1,006	1,120	1,118	1,124	1,097	1,173	1,265	1,282	4,368	4,816	5,314
Operating profit	543	585	564	578	601	579	629	650	2,270	2,458	2,696
Pre-tax profit	566	650	606	616	644	628	682	697	2,438	2,652	2,935
Net profit	472	544	510	519	523	510	555	567	2,046	2,156	2,388
Basic EPS (TWD)	6.06	7.07	6.55	6.66	6.71	6.55	7.12	7.27	26.24	27.65	30.63

Operating Ratios

Gross margin	53.3%	53.0%	52.5%	52.5%	53.1%	53.3%	52.7%	52.7%	52.8%	52.9%	53.1%
Operating margin	28.8%	27.6%	26.5%	27.0%	29.1%	26.3%	26.2%	26.7%	27.4%	27.0%	26.9%
Pre-tax margin	30.0%	30.7%	28.5%	28.8%	31.2%	28.6%	28.4%	28.7%	29.5%	29.2%	29.3%
Net margin	25.0%	25.7%	24.0%	24.2%	25.3%	23.2%	23.1%	23.3%	24.7%	23.7%	23.9%

YoY (%)

Net revenue	18.3%	30.0%	12.8%	10.9%	9.5%	4.0%	12.7%	13.7%	17.5%	10.0%	10.0%
Gross profit	14.5%	35.3%	16.9%	10.7%	9.0%	4.7%	13.1%	14.1%	18.8%	10.3%	10.3%
Operating profit	25.9%	54.3%	17.5%	11.9%	10.7%	-1.0%	11.4%	12.4%	25.6%	8.3%	9.7%
Pre-tax profit	-2.5%	68.8%	19.9%	12.5%	13.7%	-3.3%	12.6%	13.2%	20.8%	8.8%	10.7%
Net profit	-3.5%	73.6%	28.6%	21.1%	10.8%	-6.2%	8.7%	9.3%	25.7%	5.4%	10.8%

QoQ (%)

Net revenue	-2.3%	12.1%	0.7%	0.5%	-3.6%	6.5%	9.1%	1.4%			
Gross profit	-1.0%	11.4%	-0.2%	0.5%	-2.5%	6.9%	7.9%	1.4%			
Operating profit	5.0%	7.7%	-3.4%	2.4%	3.9%	-3.7%	8.7%	3.3%			
Pre-tax profit	3.4%	14.7%	-6.7%	1.7%	4.6%	-2.5%	8.6%	2.2%			
Net profit	10.2%	15.2%	-6.2%	1.7%	0.9%	-2.5%	8.7%	2.2%			

Source: Company, Daiwa forecasts


Pegavision: 2Q26 results review

(TWDm)	Pegavision's 2Q26 results	Daiwa forecast	Differ	Bloomberg consensus	Differ
Revenue	2,115	1,850	14.3%	2,092	1.1%
Gross profit	1,120	981	14.3%	1,112	0.7%
Operating profit	585	472	23.9%	591	-1.0%
Profit before tax	650	502	29.3%	602	7.9%
Net profit	544	407	33.8%	492	10.6%
Basic EPS (TWD)	7.07	5.21	35.7%	6.29	12.5%

Margin

Gross margin	53.0%	53.0%	0pp	53.2%	-0.2pp
Operating margin	27.6%	25.5%	2.1pp	28.2%	-0.6pp
Pre-tax margin	30.7%	27.2%	3.6pp	28.8%	1.9pp
Net margin	25.7%	22.0%	3.8pp	23.5%	2.2pp

Source: Company, Bloomberg, Daiwa forecasts

Pegavision: revenue by region


Source: Company, Daiwa forecasts

Pegavision: 1-year forward PER bands


Source: Bloomberg, Daiwa forecasts

Financial summary

Key assumptions

Year to 31 Dec	2021	2022	2023	2024	2025	2026E	2027E	2028E
revenue YoY growth - Other Asia (%)	49.8	12.7	7.5	(1.7)	2.5	15.0	10.0	10.0
revenue YoY growth - Taiwan (%)	(4)	21	15	1	10	15	10	10
revenue YoY growth - Other (%)	46.0	4.1	(7.7)	32.6	0.2	52.0	10.0	10.0

Profit and loss (TWDm)

Year to 31 Dec	2021	2022	2023	2024	2025	2026E	2027E	2028E
Other Asia	4,585	5,165	5,551	5,455	5,590	6,429	7,071	7,779
Taiwan	638	769	881	888	974	1,120	1,232	1,355
Other Revenue	372	387	358	474	475	723	795	874
Total Revenue	5,595	6,321	6,790	6,817	7,039	8,271	9,098	10,008
Other income	0	0	0	0	0	0	0	0
COGS	(2,631)	(3,006)	(3,122)	(2,993)	(3,361)	(3,903)	(4,282)	(4,695)
SG&A	(958)	(920)	(1,095)	(1,091)	(1,247)	(1,431)	(1,581)	(1,717)
Other op.expenses	(547)	(576)	(592)	(646)	(625)	(668)	(778)	(901)
Operating profit	1,460	1,820	1,981	2,087	1,807	2,270	2,458	2,696
Net-interest inc./(exp.)	0	(14)	(16)	(33)	(7)	118	194	240
Assoc/forex/extraord.others	(16)	11	13	79	219	50	0	0
Pre-tax profit	1,444	1,817	1,979	2,133	2,019	2,438	2,652	2,935
Tax	(196)	(272)	(301)	(279)	(368)	(373)	(477)	(528)
Min. int./pref. div./others	0	(3)	(22)	(23)	(22)	(20)	(19)	(19)
Net profit (reported)	1,249	1,542	1,656	1,831	1,628	2,046	2,156	2,388
Net profit (adjusted)	1,249	1,542	1,656	1,831	1,628	2,046	2,156	2,388
EPS (reported)(TWD)	17.837	22.031	22.827	23.470	20.872	26.241	27.649	30.627
EPS (adjusted)(TWD)	17.837	22.031	22.827	23.470	20.872	26.241	27.649	30.627
EPS (adjusted fully-diluted)(TWD)	17.718	21.843	22.614	23.243	20.615	26.054	27.452	30.409
DPS (TWD)	8.500	10.000	10.000	11.000	10.000	10.000	11.802	12.436
EBIT	1,460	1,820	1,981	2,087	1,807	2,270	2,458	2,696
EBITDA	2,117	2,753	2,918	2,814	2,581	3,158	3,403	3,701

Cash flow (TWDm)

Year to 31 Dec	2021	2022	2023	2024	2025	2026E	2027E	2028E
Profit before tax	1,444	1,817	1,979	2,133	2,019	2,438	2,652	2,935
Depreciation and amortisation	657	933	937	727	774	888	945	1,006
Tax paid	(196)	(272)	(301)	(279)	(368)	(373)	(477)	(528)
Change in working capital	1,216	(892)	(4,020)	2,506	(97)	(421)	(257)	(211)
Other operational CF items	(488)	461	2,205	(886)	331	(299)	(19)	(19)
Cash flow from operations	2,633	2,047	799	4,201	2,658	2,233	2,843	3,183
Capex	(1,841)	(1,411)	(1,112)	(3,320)	(1,409)	(1,120)	(1,000)	(1,000)
Net (acquisitions)/disposals	0	0	(2,118)	963	(617)	(334)	0	0
Other investing CF items	(9)	(18)	(168)	(120)	(110)	(4)	0	0
Cash flow from investing	(1,849)	(1,429)	(3,398)	(2,476)	(2,136)	(1,458)	(1,000)	(1,000)
Change in debt	206	67	636	(380)	118	269	0	0
Net share issues/(repurchases)	0	0	2,480	0	0	0	0	0
Dividends paid	(350)	(595)	(708)	(780)	(858)	(780)	(921)	(970)
Other financing CF items	(28)	(95)	(141)	(68)	(51)	(159)	0	0
Cash flow from financing	(172)	(623)	2,268	(1,229)	(790)	(670)	(921)	(970)
Forex effect/others	(9)	1	(15)	6	(25)	10	0	0
Change in cash	603	(3)	(346)	502	(293)	116	923	1,213
Free cash flow	792	637	(312)	881	1,250	1,114	1,843	2,183

Source: FactSet, Daiwa forecasts

Financial summary continued ...

Balance sheet (TWDm)

Year to 31 Dec	2021	2022	2023	2024	2025	2026E	2027E	2028E
Cash & short-term investment	1,916	2,513	6,234	4,258	4,481	5,222	6,145	7,358
Inventory	574	569	583	671	881	1,093	1,237	1,352
Accounts receivable	634	751	866	827	967	1,178	1,339	1,472
Other current assets	139	139	191	161	207	265	265	265
Total current assets	3,263	3,971	7,875	5,918	6,536	7,757	8,985	10,446
Fixed assets	4,915	5,037	4,724	7,860	8,729	8,767	8,822	8,816
Goodwill & intangibles	14	22	20	22	44	40	40	40
Other non-current assets	373	531	1,241	746	865	933	933	933
Total assets	8,565	9,562	13,859	14,546	16,174	17,497	18,779	20,235
Short-term debt	445	289	925	361	573	840	840	840
Accounts payable	203	195	233	199	328	361	409	447
Other current liabilities	2,131	1,958	2,148	2,230	2,917	3,568	3,568	3,568
Total current liabilities	2,778	2,442	3,307	2,790	3,818	4,769	4,817	4,855
Long-term debt	142	365	365	549	454	457	457	457
Other non-current liabilities	136	269	207	148	166	164	164	164
Total liabilities	3,056	3,076	3,879	3,487	4,438	5,391	5,438	5,476
Share capital	700	700	780	780	780	780	780	780
Reserves/R.E./others	4,786	5,727	9,128	10,186	10,851	11,229	12,484	13,921
Shareholders' equity	5,486	6,427	9,908	10,966	11,631	12,009	13,264	14,701
Minority interests	22	58	73	92	105	97	78	58
Total equity & liabilities	8,565	9,562	13,859	14,546	16,174	17,497	18,779	20,235
EV	23,965	23,471	20,400	22,016	21,923	21,444	20,502	19,270
Net debt/(cash)	(1,329)	(1,859)	(4,944)	(3,349)	(3,453)	(3,925)	(4,847)	(6,060)
BVPS (TWD)	78.372	91.821	127.022	140.595	149.117	153.967	170.048	188.472

Key ratios (%)

Year to 31 Dec	2021	2022	2023	2024	2025	2026E	2027E	2028E
Sales (YoY)	40.6	13.0	7.4	0.4	3.3	17.5	10.0	10.0
EBITDA (YoY)	44.5	30.1	6.0	(3.6)	(8.3)	22.3	7.8	8.8
Operating profit (YoY)	70.6	24.6	8.9	5.3	(13.4)	25.6	8.3	9.7
Net profit (YoY)	74.5	23.5	7.4	10.6	(11.1)	25.7	5.4	10.8
Core EPS (fully-diluted) (YoY)	74.4	23.3	3.5	2.8	(11.3)	26.4	5.4	10.8
Gross-profit margin	53.0	52.4	54.0	56.1	52.3	52.8	52.9	53.1
EBITDA margin	37.8	43.5	43.0	41.3	36.7	38.2	37.4	37.0
Operating-profit margin	26.1	28.8	29.2	30.6	25.7	27.4	27.0	26.9
Net profit margin	22.3	24.4	24.4	26.9	23.1	24.7	23.7	23.9
ROAE	24.8	25.9	20.3	17.5	14.4	17.3	17.1	17.1
ROAA	16.7	17.0	14.1	12.9	10.6	12.2	11.9	12.2
ROCE	26.4	27.5	21.5	18.0	14.6	17.3	17.5	17.6
ROIC	34.4	35.1	34.8	28.5	18.5	23.4	24.2	25.7
Net debt to equity	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Effective tax rate	13.5	15.0	15.2	13.1	18.2	15.3	18.0	18.0
Accounts receivable (days)	39.5	40.0	43.4	45.3	46.5	47.3	50.5	51.3
Current ratio (x)	1.2	1.6	2.4	2.1	1.7	1.6	1.9	2.2
Net interest cover (x)	n.a.	130.9	126.9	63.1	255.4	n.a.	n.a.	n.a.
Net dividend payout	47.7	45.4	43.8	46.9	47.9	38.1	42.7	40.6
Free cash flow yield	3.1	2.5	n.a.	3.5	4.9	4.4	7.3	8.6

Source: FactSet, Daiwa forecasts

Company profile

Founded in 2009, Pegavision is a joint venture between Kinsus and Pegatron focusing on the production and sale of soft contact lenses. Pegavision's revenue contribution from OBM (Pegavision) was 20% and ODM was 80% in 2025. The company was listed on Taiwan's main board in October 2019.

ESG analysis

ESG risks

Risks	Management	Analyst comments	
G	Executive/board quality	2	The CEO and chairperson of Pegavision are not the same individual. The company's board consists of 9 members, including 3 independent directors. We note the board members come from diverse backgrounds, indicating their capabilities in handling various challenges that may arise.
	Capital management	2	Pegavision's dividend payout ratio was only 17% for 2018, but was 38-49% over 2019-25, which we consider fair (lower than St. Shine and Ginko) due to its more aggressive capacity expansion plans. The company aims for a long-term dividend payout ratio of 50%.
	Related party & transaction	2	We note no major revenue exchange from related-party transactions; thus, we see marginal related-party risk.
S	Product quality & safety	1	Pegavision has a significantly more aggressive R&D investment strategy than peers, which we consider positive for its product quality and development going forward. As contact lenses are considered healthcare products, the company acquired international certifications for product quality and safety, including those from TFDA (Taiwan), ISO13485, CE Certificate (Europe), QMS & PMDA (Japan), NMPA (China), FDA (US) and GMP (Taiwan and Korea). It also passed the ISO14001 certification that mandates adherence to environment-related requirements. We believe Pegavision has put significant efforts in this area.
S	Selling practices & product labelling	1	Pegavision's product packaging labels and instructions for use comply with the international ISO standard for medical equipment. The company also has high after-sales service operation standards. In 2025, there were no violations of product- or service-related health and safety regulations and we do not note any specific risks in this area.

Note: Management score represents a company's ability to manage/benefit from certain ESG topics. The scores range from 1 to 3, with 1 being the strongest.

Update Date: 31 Jul 2026

Source: Daiwa, Company

Important Disclosures and Disclaimer

This publication is produced by Daiwa Securities Group Inc. and/or its non-U.S. affiliates, and distributed by Daiwa Securities Group Inc. and/or its non-U.S. affiliates, except to the extent expressly provided herein. This publication and the contents hereof are intended for information purposes only, and may be subject to change without further notice. Any use, disclosure, distribution, dissemination, copying, printing or reliance on this publication for any other purpose without our prior consent or approval is strictly prohibited. Neither Daiwa Securities Group Inc. nor any of its respective parent, holding, subsidiaries or affiliates, nor any of its respective directors, officers, servants and employees, represent nor warrant the accuracy or completeness of the information contained herein or as to the existence of other facts which might be significant, and will not accept any responsibility or liability whatsoever for any use of or reliance upon this publication or any of the contents hereof. Neither this publication, nor any content hereof, constitute, or are to be construed as, an offer or solicitation of an offer to buy or sell any of the securities or investments mentioned herein in any country or jurisdiction nor, unless expressly provided, any recommendation or investment opinion or advice. Any view, recommendation, opinion or advice expressed in this publication may not necessarily reflect those of Daiwa Securities Group Inc., and/or its affiliates nor any of its respective directors, officers, servants and employees except where the publication states otherwise. This research report is not to be relied upon by any person in making any investment decision or otherwise advising with respect to, or dealing in, the securities mentioned, as it does not take into account the specific investment objectives, financial situation and particular needs of any person.

Daiwa Securities Group Inc., its subsidiaries or affiliates, or its or their respective directors, officers and employees from time to time have trades as principals, or have positions in, or have other interests in the securities of the company under research including market making activities, derivatives in respect of such securities or may have also performed investment banking and other services for the issuer of such securities. Daiwa Securities Group Inc., its subsidiaries or affiliates do and seek to do business with the company(s) covered in this research report. Therefore, investors should be aware that a conflict of interest may exist. The following are additional disclosures.

Ownership of Securities

For "Ownership of Securities" information, please visit BlueMatrix disclosure link at <https://daiwa3.bluematrix.com/sellside/Disclosures.action>.

Investment Banking Relationship

For "Investment Banking Relationship", please visit BlueMatrix disclosure link at <https://daiwa3.bluematrix.com/sellside/Disclosures.action>.

Daiwa Securities Co. Ltd. and Daiwa Securities Group Inc.

Daiwa Securities Co. Ltd. is a subsidiary of Daiwa Securities Group Inc.

Investment Banking Relationship

Within the preceding 12 months, Daiwa Capital Markets Hong Kong Limited has lead-managed public offerings and/or secondary offerings of the equities or relevant securities of the following companies: Beijing Geekplus Technology Co Ltd (2590 HK), WeRide Inc (800 HK/ WRD US), SEYOND (2665 HK) and SENASIC Electronics Technology Co Ltd (6675 HK).

*Subsidiaries of Daiwa Securities Group Inc. for the purposes of this section shall mean any one or more of: Daiwa Capital Markets Hong Kong Limited (大和資本市場香港有限公司), Daiwa Capital Markets Singapore Limited, Daiwa Capital Markets Australia Limited, Daiwa-Cathay Capital Markets Co., Ltd., Daiwa Securities Capital Markets Korea Co., Ltd.

Within the last 12 months, the subsidiaries and/or affiliates of Daiwa Securities Group Inc. * has received compensation for investment banking services from NH Investment & Securities Co Ltd (005940 KS), E-Mart Inc (139480 KS), Samsung Securities Co Ltd (016360 KS), KT Corporation (030200 KS) and Hyundai Department Store Co Ltd (069960 KS).

Hong Kong

This research is distributed in Hong Kong by Daiwa Capital Markets Hong Kong Limited (大和資本市場香港有限公司) ("DHK") which is regulated by the Hong Kong Securities and Futures Commission. Recipients of this research in Hong Kong may contact DHK in respect of any matter arising from or in connection with this research.

Investment Banking Relationship

Within the preceding 12 months, Daiwa Capital Markets Hong Kong Limited has lead-managed public offerings and/or secondary offerings of the equities or relevant securities of the following companies: Beijing Geekplus Technology Co Ltd (2590 HK), WeRide Inc (800 HK/ WRD US), SEYOND (2665 HK) and SENASIC Electronics Technology Co Ltd (6675 HK).

Within the preceding 12 months, Daiwa Capital Markets Hong Kong Limited has received compensation for investment banking services from -.

Relevant Relationship (DHK)

DHK may from time to time have an individual employed by or associated with it serves as an officer of any of the companies under its research coverage.

Singapore

This research is distributed in Singapore by Daiwa Capital Markets Singapore Limited and it may only be distributed in Singapore to accredited investors, expert investors and institutional investors as defined in the Financial Advisers Regulations of Singapore and the Securities and Futures Act 2001 of Singapore, both as amended from time to time. By virtue of distribution to these category of investors, Daiwa Capital Markets Singapore Limited and its representatives are not required to comply with Section 45 of the Financial Advisers Act 2001 of Singapore (Section 45 relates to disclosure of Daiwa Capital Markets Singapore Limited's interest and/or any associated or connected person's interest in securities). Recipients of this research in Singapore may contact Daiwa Capital Markets Singapore Limited in respect of any matter arising from or in connection with this research.

Australia

This research is distributed in Australia by Daiwa Capital Markets Australia Limited and it may only be distributed in Australia to wholesale investors within the meaning of the Corporations Act. Recipients of this research in Australia may contact Daiwa Capital Markets Stockbroking Limited in respect of any matter arising from or in connection with the research.

Taiwan

This research is solely for reference and not intended to provide tailored investment recommendations. This research is distributed in Taiwan by Daiwa-Cathay Capital Markets Co., Ltd. and it may only be distributed in Taiwan to specific customers who have signed recommendation contracts with Daiwa-Cathay Capital Markets Co., Ltd. and non-customers including (i) professional institutional investors, (ii) TWSE or TPEX listed companies, upstream and downstream vendors, and specialists that offer or seek advice, and (iii) potential customers with an actual need for business development in accordance with the Operational Regulations Governing Securities Firms Recommending Trades in Securities to Customers. Recipients of this research including non-customer recipients of this research shall not provide it to others or engage in any activities in connection with this research which may involve conflicts of interests. Neither Daiwa-Cathay Capital Markets Co., Ltd. nor its personnel who writes or reviews the research report has any conflict of interest in this research. Since Daiwa-Cathay Capital Markets Co., Ltd. does not operate brokerage trading business in foreign markets, **this research is prepared on a "without recommendation" to any foreign securities basis** and Daiwa-Cathay Capital Markets Co., Ltd. does not accept orders from customers to trade in such foreign securities. Recipients of this research shall carefully judge their own investment risk and take full responsibility for the results of any resulting investments in the companies and/or sectors featured in this research. Without the prior written permission of Daiwa-Cathay Capital Markets Co., Ltd., recipients of this research are prohibited from disclosing the research to the media, reprinting the research, or quoting from the research to other parties. Recipients of this research in Taiwan may contact Daiwa-Cathay Capital Markets Co., Ltd. in respect of any matter arising from or in connection with the research.

Thailand

This research is distributed to only institutional investors in Thailand. This report is provided to you for informational purposes only. Information contained herein is not intended to be, and shall not be construed as, an offer or an invitation for subscription or purchase of securities in Thailand. This document has not been and will not be registered with, or approved by, the Office of the Securities and Exchange Commission of Thailand. As neither Daiwa Securities Group Inc. nor any of its subsidiaries or affiliates, nor any of the foregoing entities' respective directors, officers, servants and employees are licensed to carry on any securities business in Thailand, this document is intended to be read by the addressee who is an institutional investor only and may not be circulated or distributed, whether directly or indirectly, to the public or any members of the public in Thailand, unless to the extent permitted by applicable laws and regulations.

This report is prepared by analysts who are employed by Daiwa Securities Group Inc. and/or its non-U.S. affiliates. Neither Daiwa Securities Group Inc. nor any of its subsidiaries or affiliates, nor any of the foregoing entities' respective directors, officers, servants and employees accept any liability whatsoever for any direct or consequential loss arising from any use of this research or its contents.

The information and opinions contained herein have been compiled or arrived at from sources believed to be reliable. However, neither Daiwa Securities Group Inc. nor any of its subsidiaries or affiliates, nor any of the foregoing entities' respective directors, officers, servants and employees make any representation or warranty, express or implied, as to their accuracy or completeness. Expressions of opinion herein are subject to change without notice. The use of any information, forecasts and opinions contained in this report shall be at the sole discretion and risk of the user.

Daiwa Securities Group Inc., its subsidiaries and affiliates and their respective directors, officers, servants and employees may have positions and financial interest in securities mentioned in this research. Daiwa Securities Group Inc. and its subsidiaries and affiliates may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any entity mentioned in this research. Therefore, investors should be aware of conflict of interest that may affect the objectivity of this research.

United Kingdom

These materials constitute independent research for the purposes of the Financial Conduct Authority ("FCA") Conduct of Business Rules. These materials have been produced by Daiwa Securities Co. Ltd ("DSCL") and/or its affiliates and are distributed by Daiwa Capital Markets Europe Limited ("DCME") to persons classified as (i) eligible counterparties; and (ii) professional clients for the purposes of the Conduct of Business Rules of the FCA. These materials should not be disseminated to any retail clients in the United Kingdom. DCME is authorised and regulated by the FCA and is a member of the London Stock Exchange. DCME's FCA registration number is 124490 and the FCA's registered address is 25 The North Colonnade, London, E14 5HS.

DCME makes no representation as to the completeness, accuracy or timeliness of any of the materials produced by DSCL, and does not accept any liability for any losses, costs, liabilities or expenses which may arise directly or indirectly from any use of, or reliance on the materials.

DCME and/or its affiliates may, from time to time, to the extent permitted by law, participate or invest in, or be mandated in respect of transactions with the issuer(s) referred to in the materials prepared by DSCL, perform services for or solicit business from such issuers, and/or have a position or effect transactions in a particular issuer's securities and/or may have acted as an underwriter during the past twelve months in respect of a particular issuer of its securities. DCME does not review DSCL's materials prior to publication on DCME's platforms and has no influence over its content. DCME has in place organisational arrangements for the prevention and avoidance of conflicts of interest, including information barriers to control the flow of information between the private and public sides of the firm. A summary of DCME's conflict management policies are available at <http://www.uk.daiwacm.com/about-us/corporate-governance-regulatory>.

DSCL's materials are distributed by DCME only as permitted by law. The materials are not directed to, or intended for distribution to or use by, any person or entity located in any jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or would subject DCME to any regulation or licensing requirement within such jurisdiction.

Germany

Research reports are produced by Daiwa Securities Co. Ltd. and/or its affiliates and are distributed by Daiwa Capital Markets Deutschland GmbH in the European Union. Daiwa Capital Markets Deutschland GmbH is authorised and regulated by Bundesanstalt für Finanzdienstleistungsaufsicht ("BaFin") under the reference number 149361. Daiwa Capital Markets Deutschland GmbH and its affiliates may, from time to time, to the extent permitted by law, participate or invest in, or be mandated in respect of, other financing transactions with the issuer(s) of the securities referred to herein (the "Securities"), perform services for or solicit business from such issuers, and/or have a position or effect transactions in the Securities or options thereof.

This publication is intended for investors who are Professional Clients or Eligible Counterparties in the European Union within the meaning of Directive 2014/65/EU ("MiFID II") and should therefore not be distributed to Retail Clients in the European Union.

Daiwa Capital Markets Deutschland GmbH has in place organisational arrangements for the identification, prevention and management of conflicts of interest. Information regarding our conflict management are available at: <https://www.de.daiwacm.com/policies/>

Additional disclosures regarding specific company names and related financial instruments are available at: <https://daiwa3.bluematrix.com/sellside/Disclosures.action>.

Bahrain

This research material is distributed in Bahrain by Daiwa Capital Markets Europe Limited, Bahrain Branch, regulated by The Central Bank of Bahrain and holds Investment Business Firm – Category 2 license and having its official place of business at the Bahrain World Trade Centre, South Tower, 7th floor, P.O. Box 30069, Manama, Kingdom of Bahrain. Tel No. +973 17534452 Fax No. +973 535113

United States

This research is distributed into the United States directly by Daiwa Capital Markets Hong Kong Limited (DCMHK) and in certain cases indirectly by Daiwa Capital Markets America Inc. (DCMA), a U.S. Securities and Exchange Commission registered broker-dealer and FINRA member firm, exclusively to "major U.S. institutional investors", as defined under Rule 15a-6 promulgated under the U.S. Securities Exchange Act of 1934, as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission (SEC). Where this is co-branded research published by Daiwa's partners in collaboration with other parties not affiliated with Daiwa, this research is distributed in the United States by DCMHK only. This report is not an offer to sell or the solicitation of any offer to buy securities. U.S. customers wishing to effect transactions in any designated investment discussed in this report should do so through a qualified salesperson of DCMA. Non-U.S. customers wishing to effect transactions in any designated investment discussed in this report should contact a Daiwa entity in their local jurisdiction. The securities or other investment products discussed in this report may not be eligible for sale in some jurisdictions.

Analysts employed outside the U.S., as specifically indicated elsewhere in this report, are not registered as research analysts with FINRA. These analysts may not be associated persons of DCMA, and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

ADDITIONAL IMPORTANT DISCLOSURES CAN BE FOUND AT:

<https://daiwa3.bluematrix.com/sellside/Disclosures.action>

Ownership of Securities

For "Ownership of Securities" information please visit BlueMatrix disclosure link at <https://daiwa3.bluematrix.com/sellside/Disclosures.action>.

Investment Banking Relationships

For "Investment Banking Relationships" please visit BlueMatrix disclosure link at <https://daiwa3.bluematrix.com/sellside/Disclosures.action>.

DCMA Market Making

For "DCMA Market Making" please visit BlueMatrix disclosure link at <https://daiwa3.bluematrix.com/sellside/Disclosures.action>.

Research Analyst Conflicts

For updates on "Research Analyst Conflicts" please visit BlueMatrix disclosure link at <https://daiwa3.bluematrix.com/sellside/Disclosures.action>. The principal research analysts who prepared this report have no financial interest in securities of the issuers covered in the report, are not (nor are any members of their household) an officer, director or advisory board member of the issuer(s) covered in the report, and are not aware of any material relevant conflict of interest involving the analyst or DCMA, and did not receive any compensation from the issuer during the past 12 months except as noted: no exceptions.

Research Analyst Certification

For updates on "Research Analyst Certification" and "Rating System" please visit BlueMatrix disclosure link at <https://daiwa3.bluematrix.com/sellside/Disclosures.action>. The views about any and all of the subject securities and issuers expressed in this Research Report accurately reflect the personal views of the research analyst(s) primarily responsible for this report (or the views of the firm producing the report if no individual analyst is named on the report); and no part of the compensation of such analyst (or no part of the compensation of the firm if no individual analyst is named on the report) was, is, or will be directly or indirectly related to the specific recommendations or views contained in this Research Report.

The following explains the rating system in the report as compared to relevant local indices, unless otherwise stated, based on the beliefs of the author of the report.

- "1": the security could outperform the local index by more than 15% over the next 12 months.
- "2": the security is expected to outperform the local index by 5-15% over the next 12 months.
- "3": the security is expected to perform within 5% of the local index (better or worse) over the next 12 months.
- "4": the security is expected to underperform the local index by 5-15% over the next 12 months.
- "5": the security could underperform the local index by more than 15% over the next 12 months.

Disclosure of investment ratings

Rating	Percentage of total
Buy*	72.63%
Hold**	20.53%
Sell***	6.84%

Source: Daiwa

Notes: data is for single-branded Daiwa research in Asia (ex Japan) and correct as of 30 June 2026.

* comprised of Daiwa's Buy and Outperform ratings.

** comprised of Daiwa's Hold ratings.

*** comprised of Daiwa's Underperform and Sell ratings.

Additional information may be available upon request.

Japan - Notification items pursuant to Article 37 of the Financial Instruments and Exchange Law

(This Notification is only applicable to where report is distributed by Daiwa Securities Co. Ltd.)

If you decide to enter into a business arrangement with our company based on the information described in this report, we ask you to pay close attention to the following items.

- In addition to the purchase price of a financial instrument, our company will collect a trading commission* for each transaction as agreed beforehand with you. Since commissions may be included in the purchase price or may not be charged for certain transactions, we recommend that you confirm the commission for each transaction. In some cases, our company also may charge a maximum of ¥2 million per year as a standing proxy fee for our deposit of your securities, if you are a non-resident.
- For derivative and margin transactions etc., our company may require collateral or margin requirements in accordance with an agreement made beforehand with you. Ordinarily in such cases, the amount of the transaction will be in excess of the required collateral or margin requirements**.
- There is a risk that you will incur losses on your transactions due to changes in the market price of financial instruments based on fluctuations in interest rates, exchange rates, stock prices, real estate prices, commodity prices, and others. In addition, depending on the content of the transaction, the loss could exceed the amount of the collateral or margin requirements.
- There may be a difference between bid price etc. and ask price etc. of OTC derivatives handled by our company.
- Before engaging in any trading, please thoroughly confirm accounting and tax treatments regarding your trading in financial instruments with such experts as certified public accountants.

* The amount of the trading commission cannot be stated here in advance because it will be determined between our company and you based on current market conditions and the content of each transaction etc.

** The ratio of margin requirements etc. to the amount of the transaction cannot be stated here in advance because it will be determined between our company and you based on current market conditions and the content of each transaction etc.

When making an actual transaction, please be sure to carefully read the materials presented to you prior to the execution of agreement, and to take responsibility for your own decisions regarding the signing of the agreement with our company.

Corporate Name:	Daiwa Securities Co. Ltd.
Registered:	Financial Instruments Business Operator, Chief of Kanto Local Finance Bureau (Kin-sho) No.108
Memberships:	Japan Securities Dealers Association, The Financial Futures Association of Japan, Japan Investment Advisers Association, Type II Financial Instruments Firms Association, Japan Security Token Offering Association